{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:59:27Z","timestamp":1781632767299,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kafr El Shiekh University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) remains a cornerstone for preventing ischemic events; however, the optimal long-term single antiplatelet therapy after completion of DAPT remains unclear. We aimed to compare clopidogrel and aspirin monotherapy after completion of the standard duration of DAPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted on PubMed, Scopus, Cochrane Library, and Web of Science from inception to April 2025. We included randomized clinical trials and observational studies that compared aspirin versus clopidogrel monotherapy after completion of standard-duration DAPT. The primary and co-primary outcomes were major adverse cardiovascular events (MACE) and major bleeding, respectively. Using random-effects models, outcomes were expressed as risk ratios (RR) or hazard ratios (HR) with 95% confidence intervals (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten studies, comprising 162,829 patients, were included. Clopidogrel was significantly associated with a lower risk of MACE (HR: 0.72, 95% CI: 0.66\u20130.79) and net adverse clinical events (NACE) (RR: 0.86, 95% CI: 0.73\u20130.99) at a weighted mean follow-up of 3.2 years. Major bleeding showed no significant difference between clopidogrel and aspirin (RR: 0.85, 95% CI: 0.60\u20131.21). Moreover, there was no difference between clopidogrel and aspirin in all-cause mortality, myocardial infarction, revascularization, stroke, or all bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients who underwent PCI, clopidogrel monotherapy after standard DAPT was associated with a lower incidence of MACE and NACE compared with aspirin monotherapy, without increasing the bleeding risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-025-03942-3","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:01:32Z","timestamp":1770361292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clopidogrel versus aspirin monotherapy following dual antiplatelet therapy after percutaneous coronary intervention: an updated meta-analysis of 162,829 patients"],"prefix":"10.1007","volume":"82","author":[{"given":"Mohammed A.","family":"Elbahloul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Galal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa M.","family":"Moawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Wahdan","family":"Kasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman E.","family":"Labeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam Y.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"17","key":"3942_CR1","doi-asserted-by":"publisher","first-page":"E1371","DOI":"10.4244\/EIJ-D-21-00904","volume":"17","author":"DJ Angiolillo","year":"2022","unstructured":"Angiolillo DJ, Galli M, Collet JP, Kastrati A, O\u2019Donoghue ML (2022) Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 17(17):E1371\u2013E1396","journal-title":"EuroIntervention"},{"key":"3942_CR2","doi-asserted-by":"crossref","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH et al (2025) ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation [Internet]. 2025 Feb 27 [cited 2025 Jun 24]; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40014670","DOI":"10.1161\/CIR.0000000000001309"},{"issue":"36","key":"3942_CR3","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J et al (2024) 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 45(36):3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177","journal-title":"Eur Heart J"},{"key":"3942_CR4","doi-asserted-by":"publisher","unstructured":"Kaul S, Brophy JM (2025) The 2025 guideline update endorses ticagrelor monotherapy after \u2265\u20091 month of DAPT post-PCI in patients with ACS: is the evidence conclusive? J Am Coll Cardiol 85(22):2083\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2025.04.040","DOI":"10.1016\/j.jacc.2025.04.040"},{"key":"3942_CR5","doi-asserted-by":"crossref","unstructured":"Carvalho PEP, Gewehr DM, Nascimento BR, Melo L, Burkhardt G, Rivera A et al (2024) Short-term dual antiplatelet therapy after drug-eluting stenting in patients with acute coronary syndromes: a systematic review and network meta-analysis. JAMA Cardiol 9(12):1094\u2013105.\u00a0https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2824179","DOI":"10.1001\/jamacardio.2024.3216"},{"key":"3942_CR6","doi-asserted-by":"publisher","unstructured":"Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C et al (2019) Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med 381(21):2032\u20132042. https:\/\/doi.org\/10.1056\/NEJMoa1908419","DOI":"10.1056\/NEJMoa1908419"},{"issue":"9678","key":"3942_CR7","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"R Collins","year":"2009","unstructured":"Collins R, Peto R, Hennekens C, Doll R, Bubes V, Buring J et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849\u20131860","journal-title":"Lancet"},{"key":"3942_CR8","doi-asserted-by":"crossref","unstructured":"Giacoppo D, Gragnano F, Watanabe H, Kimura T, Kang J, Park KW et al (2025) P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. BMJ 389. https:\/\/www.bmj.com\/content\/389\/bmj-2024-082561","DOI":"10.1136\/bmj-2024-082561"},{"key":"3942_CR9","doi-asserted-by":"publisher","unstructured":"Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R et al (2024) Clopidogrel vs Aspirin monotherapy byond 1 year after percutaneous coronary intervention. J Am Coll Cardiol 83(1):17\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.013","DOI":"10.1016\/j.jacc.2023.10.013"},{"issue":"47","key":"3942_CR10","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1093\/eurheartj\/ehae617","volume":"45","author":"H Watanabe","year":"2024","unstructured":"Watanabe H, Natsuaki M, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R et al (2024) Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial. Eur Heart J 45(47):5042\u201354. https:\/\/doi.org\/10.1093\/eurheartj\/ehae617","journal-title":"Eur Heart J"},{"key":"3942_CR11","doi-asserted-by":"publisher","unstructured":"Capodanno D, Angiolillo DJ (2023) Long-term P2Y12Inhibitor or aspirin as single antiplatelet therapy in patients with previous percutaneous coronary intervention. Circulation 147(2):118\u2013121.\u00a0https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.063004","DOI":"10.1161\/CIRCULATIONAHA.122.063004"},{"key":"3942_CR12","doi-asserted-by":"crossref","unstructured":"Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB et al (2021) Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 397(10293):2487\u201396. https:\/\/www.thelancet.com\/action\/showFullText?pii=S0140673621010631","DOI":"10.1016\/S0140-6736(21)01063-1"},{"key":"3942_CR13","doi-asserted-by":"publisher","unstructured":"Kang J, Park KW, Lee H, Hwang D, Yang HM, Rha SW et al (2023) Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the host-exam extended study. Circulation 147(2):108\u201317.\u00a0https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062770","DOI":"10.1161\/CIRCULATIONAHA.122.062770"},{"key":"3942_CR14","doi-asserted-by":"crossref","unstructured":"Tan BEX, Wong PY, Baibhav B, Thakkar S, Azhar AZ, Rao M et al (2023) Clopidogrel Vs Aspirin monotherapy following dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and meta-analysis. Curr Probl Cardiol 48(8):101174. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0146280622000718?via%3Dihub","DOI":"10.1016\/j.cpcardiol.2022.101174"},{"key":"3942_CR15","doi-asserted-by":"crossref","unstructured":"Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH et al (2025) Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial. Lancet 405(10486):1252\u20131263.\u00a0https:\/\/www.thelancet.com\/action\/showFullText?pii=S0140673625004490","DOI":"10.1016\/S0140-6736(25)00449-0"},{"key":"3942_CR16","doi-asserted-by":"publisher","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP et al (2019) Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142","DOI":"10.1002\/14651858.ED000142"},{"key":"3942_CR17","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372. https:\/\/www.bmj.com\/content\/372\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"3942_CR18","doi-asserted-by":"crossref","unstructured":"Flemyng E, Moore TH, Boutron I, Higgins JPT, Hr\u00f3bjartsson A, Nejstgaard CH et al (2023) Using risk of bias 2 to assess results from randomised controlled trials: guidance from Cochrane. BMJ Evid Based Med 28(4):260\u2013266. https:\/\/ebm.bmj.com\/content\/28\/4\/260","DOI":"10.1136\/bmjebm-2022-112102"},{"issue":"9","key":"3942_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"3942_CR20","doi-asserted-by":"publisher","unstructured":"Srinivasan R, Ramachandran GN, El-Manzalawy Y, Honavar V (2013) Benjamini\u2013Hochberg method. Encyclopedia of Systems Biology 78\u201378. https:\/\/doi.org\/10.1007\/978-1-4419-9863-7_1215","DOI":"10.1007\/978-1-4419-9863-7_1215"},{"key":"3942_CR21","doi-asserted-by":"crossref","unstructured":"Higgins J, Thompson S, Deeks J, Bmj DA (2003) undefined Measuring inconsistency in meta-analyses. bmj.comJPT Higgins, SG Thompson, JJ Deeks, DG AltmanBmj, 2003\u2022bmj.com [Internet]. [cited 2025 Feb 15]; Available from: https:\/\/www.bmj.com\/content\/327\/7414\/557.short","DOI":"10.1136\/bmj.327.7414.557"},{"key":"3942_CR22","doi-asserted-by":"crossref","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/9310563\/","DOI":"10.1136\/bmj.315.7109.629"},{"issue":"4","key":"3942_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ Van Der Weele","year":"2017","unstructured":"Van Der Weele TJ, Ding P (2017) Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med 167(4):268\u2013274 (https:\/\/pubmed.ncbi.nlm.nih.gov\/28693043\/)","journal-title":"Ann Intern Med"},{"issue":"4","key":"3942_CR24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1536867X1801700402","volume":"17","author":"Y Wei","year":"2017","unstructured":"Wei Y, Royston P (2017) Reconstructing time-to-event data from published kaplan-meier curves. Stata J 17(4):786\u2013802","journal-title":"Stata J"},{"key":"3942_CR25","doi-asserted-by":"crossref","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ (2012) Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12. https:\/\/pubmed.ncbi.nlm.nih.gov\/22297116\/","DOI":"10.1186\/1471-2288-12-9"},{"key":"3942_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.3348","author":"JH Cho","year":"2024","unstructured":"Cho JH (2024) Clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention - a nationwide population-based study. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.3348","journal-title":"Eur Heart J"},{"key":"3942_CR27","doi-asserted-by":"publisher","unstructured":"Jang JY, Yu GI, Ahn J, Bae JS, Cho YH, Kang MG et al (2025) Optimal long-term antiplatelet regimen for patients with high ischaemic and bleeding risks after percutaneous coronary intervention. Thromb Haemost. http:\/\/www.thieme-connect.com\/products\/ejournals\/html\/https:\/\/doi.org\/10.1055\/a-2499-5458","DOI":"10.1055\/a-2499-5458"},{"key":"3942_CR28","doi-asserted-by":"publisher","unstructured":"Lan K, Gao H, Gong H (2024) A retrospective study of the safety and efficacy of clopidogrel versus aspirin monotherapy one year after coronary stent implantation. BMC Pharmacol Toxicol 25(1):67. https:\/\/link.springer.com\/articles\/https:\/\/doi.org\/10.1186\/s40360-024-00796-w","DOI":"10.1186\/s40360-024-00796-w"},{"key":"3942_CR29","doi-asserted-by":"publisher","unstructured":"Park TK, Song Y, Bin, Ahn J, Carriere KC, Hahn JY, Yang JH et al (2016) Clopidogrel versus aspirin as an antiplatelet monotherapy after 12-month dual-antiplatelet therapy in the era of drug-eluting stents. Circ Cardiovasc Interv 9(1). https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.115.002816","DOI":"10.1161\/CIRCINTERVENTIONS.115.002816"},{"issue":"2","key":"3942_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4070\/kcj.2019.0166","volume":"50","author":"DS Sim","year":"2020","unstructured":"Sim DS, Jeong MH, Kim HS, Gwon HC, Seung KB, Rha SW et al (2020) Clopidogrel versus aspirin after dual antiplatelet therapy in acute myocardial infarction patients undergoing drug-eluting stenting. Korean Circ J 50(2):120\u20139. https:\/\/doi.org\/10.4070\/kcj.2019.0166","journal-title":"Korean Circ J"},{"key":"3942_CR31","unstructured":"Zhuang XD, Long M, Li CL, Hu CH, Du ZM, Liao XX (2014) Efficacy and safety of low-dose clopidogrel after 12-month dual antiplatelet therapy for patients having drug-eluting stent implantation. J Thorac Dis 6(5):459.\u00a0https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4015003\/"},{"key":"3942_CR32","doi-asserted-by":"crossref","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A et al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 4(38):3720\u20133826.\u00a0https:\/\/academic.oup.com\/eurheartj\/article\/44\/38\/3720\/7243210","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"3942_CR33","doi-asserted-by":"publisher","unstructured":"Piccolo R, Calabr\u00f2 P, Carrara G, Simonetti F, Varricchio A, Attisano T et al\u00a0(2025) Personalized or standard duration of dual antiplatelet therapy after percutaneous coronary intervention: the PARTHENOPE randomized trial. J Am Coll Cardiol.\u00a0https:\/\/doi.org\/10.1016\/j.jacc.2025.08.040","DOI":"10.1016\/j.jacc.2025.08.040"},{"issue":"6","key":"3942_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamacardio.2024.0534","volume":"9","author":"Y Li","year":"2024","unstructured":"Li Y, Li J, Wang B, Jing Q, Zeng Y, Hou A et al (2024) Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial. JAMA Cardiol 9(6):523\u2013531 (https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2817471)","journal-title":"JAMA Cardiol"},{"issue":"3","key":"3942_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI20986","volume":"113","author":"RT Dorsam","year":"2004","unstructured":"Dorsam RT, Kunapuli SP (2004) Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113(3):340\u2013345","journal-title":"J Clin Invest"},{"key":"3942_CR36","doi-asserted-by":"publisher","unstructured":"Cattaneo M (2015) P2Y12 receptors: Structure and function. J Throm Haemos 13(S1):S10\u20136.\u00a0https:\/\/doi.org\/10.1111\/jth.12952","DOI":"10.1111\/jth.12952"},{"issue":"12","key":"3942_CR37","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3390\/jcm10122720","volume":"10","author":"HW Park","year":"2021","unstructured":"Park HW, Kang MG, Ahn JH, Bae JS, Tantry US, Gurbel PA et al (2021) Effects of monotherapy with clopidogrel vs. Aspirin on vascular function and hemostatic measurements in patients with coronary artery disease: The prospective, crossover i-love-mono trial. J Clin Med 10(12):2720 (https:\/\/www.mdpi.com\/2077-0383\/10\/12\/2720\/htm)","journal-title":"J Clin Med"},{"key":"3942_CR38","doi-asserted-by":"publisher","unstructured":"Nelson TA, Parker WAE, Ghukasyan Lakic T, Westerbergh J, James SK, Siegbahn A et al (2022) Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. Platelets 33(3):425\u201331.\u00a0https:\/\/www.tandfonline.com\/doi\/pdf\/https:\/\/doi.org\/10.1080\/09537104.2021.1934667","DOI":"10.1080\/09537104.2021.1934667"},{"key":"3942_CR39","doi-asserted-by":"publisher","unstructured":"Tasoudis PT, Kyriakoulis IG, Sagris D, Diener HC, Ntaios G (2022) Clopidogrel monotherapy versus aspirin monotherapy in patients with established cardiovascular disease: systematic review and meta-analysis. Thromb Haemost 122(11):1879\u201387.\u00a0https:\/\/doi.org\/10.1055\/a-1853-2952","DOI":"10.1055\/a-1853-2952"},{"key":"3942_CR40","doi-asserted-by":"crossref","unstructured":"Gent M (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038):1329\u20131339.\u00a0https:\/\/www.thelancet.com\/action\/showFullText?pii=S0140673696094573","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"3942_CR41","doi-asserted-by":"crossref","unstructured":"Cheng-Yan HU, Yan-Ling WANG, Zhen-Xing FAN, Xi-Peng SUN, Shuai WANG, Zhi LIU Effect of cytochrome P450 2C19 (CYP2C19) gene polymorphism and clopidogrel reactivity on long term prognosis of patients with coronary heart disease after PCI. J Geriatr Cardiol 21(1):90.\u00a0https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10908579\/","DOI":"10.26599\/1671-5411.2024.01.004"},{"key":"3942_CR42","doi-asserted-by":"crossref","unstructured":"Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T et al (2013) Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis 106(10):517\u201327.\u00a0https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1875213613002805","DOI":"10.1016\/j.acvd.2013.06.055"},{"key":"3942_CR43","doi-asserted-by":"crossref","unstructured":"Gargiulo G, Costa F, Ariotti S, Biscaglia S, Campo G, Esposito G et al (2016) Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J 174:95\u2013102.\u00a0https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0002870316000314","DOI":"10.1016\/j.ahj.2016.01.015"},{"key":"3942_CR44","doi-asserted-by":"crossref","unstructured":"O\u2019Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y et al (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374(9694):989\u201397.\u00a0https:\/\/www.thelancet.com\/action\/showFullText?pii=S0140673609615257","DOI":"10.1016\/S0140-6736(09)61525-7"},{"key":"3942_CR45","doi-asserted-by":"publisher","unstructured":"Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ et al (2012) Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet Inhibition and patient outcomes trial. Circulation 125(8):978\u2013986.\u00a0https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.032912","DOI":"10.1161\/CIRCULATIONAHA.111.032912"},{"key":"3942_CR46","doi-asserted-by":"crossref","unstructured":"Oliva A, Castiello DS, Franzone A, Condorelli G, Colombo A, Esposito G et al (2023) P2Y12 inhibitors monotherapy in patients undergoing complex vs non-complex percutaneous coronary intervention: a meta-analysis of randomized trials. Am Heart J 255:71\u201381.\u00a0https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0002870322002010","DOI":"10.1016\/j.ahj.2022.10.006"},{"key":"3942_CR47","doi-asserted-by":"crossref","unstructured":"Megna R, Petretta M, Nappi C, Assante R, Zampella E, Gaudieri V et al (2023) Age-specific cardiovascular risk factors for major adverse cardiac events in patients undergoing myocardial perfusion imaging. J Cardiov Dev Dis 10(9):395.\u00a0https:\/\/www.mdpi.com\/2308-3425\/10\/9\/395\/htm","DOI":"10.3390\/jcdd10090395"},{"key":"3942_CR48","doi-asserted-by":"crossref","unstructured":"Ali MA, Raja HAA, Ali A, Bacha Z, Sethi FA, Khan NA et al (2025) Efficacy and safety of clopidogrel versus aspirin monotherapy after percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. Cardiol Rev https:\/\/journals.lww.com\/cardiologyinreview\/fulltext\/9900\/efficacy_and_safety_of_clopidogrel_versus_aspirin.521.aspx","DOI":"10.1097\/CRD.0000000000000971"},{"key":"3942_CR49","doi-asserted-by":"crossref","unstructured":"Laudani C, Giacoppo D, Occhipinti G, Galli M, Greco A, Spagnolo M et al (2025) Aspirin or P2Y12 inhibitor monotherapy after percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv 18(15):1848\u20131859. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1936879825016541","DOI":"10.1016\/j.jcin.2025.05.044"},{"key":"3942_CR50","doi-asserted-by":"crossref","unstructured":"Wani SA, Naveed MA, Azeem B, Ashraf S, Ali A, Ali T et al (2025) Comparative outcomes of clopidogrel vs aspirin monotherapy in post- pci patients: an updated systematic review and meta-analysis. Cardiov Revasc Med\u00a0https:\/\/www.sciencedirect.com\/science\/article\/pii\/S155383892500291X#s0040","DOI":"10.1016\/j.carrev.2025.06.006"},{"key":"3942_CR51","doi-asserted-by":"publisher","unstructured":"Sibbing D, Nicolas J, Spirito A, Vogel B, Cao D, Stipek W et al (2024) Clopidogrel versus aspirin as monotherapy following dual antiplatelet therapy in patients with acute coronary syndrome receiving a drug-eluting stent: a systematic literature review and meta-analysis. Clin Cardiol 47(9):e24326. https:\/\/doi.org\/10.1002\/clc.24326","DOI":"10.1002\/clc.24326"},{"key":"3942_CR52","doi-asserted-by":"publisher","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LPC, Demeter SH et al (2023) AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart Association\/American college of cardiology joint committee on clinical practice guidelines. J Am Coll Cardiol 82(9):833\u2013955. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.003","DOI":"10.1016\/j.jacc.2023.04.003"},{"key":"3942_CR53","doi-asserted-by":"publisher","first-page":"994184","DOI":"10.3389\/fcvm.2022.994184","volume":"9","author":"YW Chen","year":"2022","unstructured":"Chen YW, Liao YJ, Chang WC, Hsiao TH, Lin CH, Hsu CY et al (2022) CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel. Front Cardiovasc Med 9:994184","journal-title":"Front Cardiovasc Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03942-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03942-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03942-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:39:14Z","timestamp":1781631554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03942-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3942"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03942-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed and agreed on the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}